Predictors of treatment failure and outcome assessment of extracorporeal shock wave lithotripsy with the Dornier Compact Delta® III Pro: experience from the first 1000 treatments.
Morshed Salah, Maged Al-Ghashmi, Bela Tallai, Abu Baker, Mohammed Ibrahim, Tawiz Gul, Hatem Kamkoum, Salvan Alhabash, Hossameldin Alnawsara, Abdoulhafid Elmogassabi, Maged Alrayashi, Mohammed Ebrahim, Mohamed Abdelkareem, Faisal Ahmed
{"title":"Predictors of treatment failure and outcome assessment of extracorporeal shock wave lithotripsy with the Dornier Compact Delta® III Pro: experience from the first 1000 treatments.","authors":"Morshed Salah, Maged Al-Ghashmi, Bela Tallai, Abu Baker, Mohammed Ibrahim, Tawiz Gul, Hatem Kamkoum, Salvan Alhabash, Hossameldin Alnawsara, Abdoulhafid Elmogassabi, Maged Alrayashi, Mohammed Ebrahim, Mohamed Abdelkareem, Faisal Ahmed","doi":"10.4081/aiua.2025.13867","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The Dornier Compact Delta® III Pro is a next-generation extracorporeal shock wave lithotripter featuring flat-panel detector technology for enhanced imaging and a compact modular design. This study evaluates treatment outcomes and predictors of failure for this system, representing the first published clinical experience.</p><p><strong>Methods: </strong>We retrospectively analyzed the first 1,000 consecutive patients treated with the Dornier Compact Delta® III Pro for renal or ureteric stones between May 2022 and November 2023 at a secondary hospital. Stone-free status was assessed via radiography, ultrasonography, or computed tomography (CT) within three months post-treatment. Predictive factors for treatment failure were identified through univariate and multivariate logistic regression analyses.</p><p><strong>Results: </strong>The cohort had a median age of 37 years (IQR: 32- 44.2) and a body mass index (BMI) of 26 kg/m² (IQR: 24-29). Key characteristics included: prior urologic interventions in 36.6% of patients, single stones in 79.8% (median size 9 mm, IQR: 7-10), a median stone density of 1000 Hounsfield Units (HU) (IQR: 760-1200), and hydronephrosis observed in 55.3% of cases. Initial ESWL success was achieved in 80.5% of cases, increasing to 87.5% following repeat sessions (mean treatments: 1.2). Multivariate analysis identified four independent predictors of treatment failure: prior urologic intervention (adjusted odds ratio [aOR] 2.64, 95% CI 1.75-4.00, p<0.001), multiple stones (aOR 0.45, 95% CI 0.24-0.77, p = 0.011), increased skin-to-stone distance (per cm: aOR 1.18, 95% CI 1.06-1.30, p<0.001), and higher stone density (per 100 HU: aOR 1.12, 95% CI 1.06-1.18, p<0.001).</p><p><strong>Conclusions: </strong>The Dornier Compact Delta® III Pro achieved an 87.3% stone-free rate with failure predictors consistent with established lithotripsy literature. These findings support the adoption of this device as an effective ESWL system, particularly for institutions prioritizing advanced imaging and a space-efficient design.</p>","PeriodicalId":46900,"journal":{"name":"Archivio Italiano di Urologia e Andrologia","volume":" ","pages":"13867"},"PeriodicalIF":1.3000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivio Italiano di Urologia e Andrologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/aiua.2025.13867","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The Dornier Compact Delta® III Pro is a next-generation extracorporeal shock wave lithotripter featuring flat-panel detector technology for enhanced imaging and a compact modular design. This study evaluates treatment outcomes and predictors of failure for this system, representing the first published clinical experience.
Methods: We retrospectively analyzed the first 1,000 consecutive patients treated with the Dornier Compact Delta® III Pro for renal or ureteric stones between May 2022 and November 2023 at a secondary hospital. Stone-free status was assessed via radiography, ultrasonography, or computed tomography (CT) within three months post-treatment. Predictive factors for treatment failure were identified through univariate and multivariate logistic regression analyses.
Results: The cohort had a median age of 37 years (IQR: 32- 44.2) and a body mass index (BMI) of 26 kg/m² (IQR: 24-29). Key characteristics included: prior urologic interventions in 36.6% of patients, single stones in 79.8% (median size 9 mm, IQR: 7-10), a median stone density of 1000 Hounsfield Units (HU) (IQR: 760-1200), and hydronephrosis observed in 55.3% of cases. Initial ESWL success was achieved in 80.5% of cases, increasing to 87.5% following repeat sessions (mean treatments: 1.2). Multivariate analysis identified four independent predictors of treatment failure: prior urologic intervention (adjusted odds ratio [aOR] 2.64, 95% CI 1.75-4.00, p<0.001), multiple stones (aOR 0.45, 95% CI 0.24-0.77, p = 0.011), increased skin-to-stone distance (per cm: aOR 1.18, 95% CI 1.06-1.30, p<0.001), and higher stone density (per 100 HU: aOR 1.12, 95% CI 1.06-1.18, p<0.001).
Conclusions: The Dornier Compact Delta® III Pro achieved an 87.3% stone-free rate with failure predictors consistent with established lithotripsy literature. These findings support the adoption of this device as an effective ESWL system, particularly for institutions prioritizing advanced imaging and a space-efficient design.